ADMA Biologics
ADMA
Market cap $4.42B

18.51 USD

+0.04

0.22%

At close Jul 11, 4:00 PM EDT

After hours

18.22

-0.29

1.57%

1 day

0.22%

5 days

1.31%

1 month

-15.36%

3 months

-4.59%

6 months

12.25%

Year to date

3.01%

1 year

50.37%

5 years

570.65%

10 years

92.21%

About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Employees: 685

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

312% more call options, than puts

Call options by funds: $67.2M | Put options by funds: $16.3M

86% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 36

20% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 6 (+1) [Q1 2025]

15% more capital invested

Capital invested by funds: $3.5B [Q4 2024] → $4.04B (+$538M) [Q1 2025]

13% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 112

8% more funds holding

Funds holding: 319 [Q4 2024] → 344 (+25) [Q1 2025]

0.29% less ownership

Funds ownership: 86.29% [Q4 2024] → 86.0% (-0.29%) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$32

73%

upside

Avg. target

$32

73%

upside

High target

$32

73%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Raymond James

Elliot Wilbur

73%upside

$32

Strong Buy

Maintained

8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about ADMA published over the past 30 days

Zacks Investment Research

Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know

Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.

Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know

Zacks Investment Research

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Zacks Investment Research

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

Zacks Investment Research

Will Strong Asceniv Sales Drive ADMA Biologics Further?

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

Will Strong Asceniv Sales Drive ADMA Biologics Further?

Zacks Investment Research

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Zacks Investment Research

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

Zacks Investment Research

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

ADMA's revenue growth has plateaued over the last three quarters, raising concerns about near-term momentum and justifying a shift to a neutral stance. Despite strong fundamentals and a promising long-term outlook, recent earnings misses and weak sequential sales make the current risk/reward profile less attractive. Given limited upside and better opportunities elsewhere, I have taken profits and will reconsider if quarter-over-quarter growth reaccelerates or the stock pulls back.

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

Zacks Investment Research

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

Zacks Investment Research

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

See News Rankings

Charts implemented using Lightweight Charts™